Trial Site Detail

 

Drug:
Apatinib Mesylate
Trial:
Apatinib Mesylate (Rivoceranib) Versus Standard Second-line TKI in the Treatment of Advanced GIST
Conditions: Gastrointestinal Stromal Tumor
Trial Status:
Recruiting

 

Xiangya Hospital Central South University

     
Changsha , Hunan 410013
China

 

Principal Investigator:
 Heli Liu, PhD
Contact:
 Gang Cheng, PhD 15111489917 gangcheng0307@163.com
Activation Status of this Site:
 Active
Notes about this Site:
Xiangya Hospital Central South University Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.